

12 Aug 2022 | News

# Inflation, Supply Chain And Private Label Pressures: Consumer Health Leaders Talk 'Big Picture' Challenges

by

OTC drug and dietary supplement companies continue to face significant economic and competitive issues in what continues to be a highly volatile operating environment. Here we've culled takes from top execs at Sanofi, Bayer, J&J, P&G and other leading players, provided during recent sales and earnings presentations.

Lots of talk of macroeconomic headwinds in consumer health companies' quarterly earnings calls of late. CEOs and other top execs at Sanofi, Bayer, Reckitt, Prestige Consumer Healthcare, Johnson & Johnson, Procter & Gamble, Abbott, Church & Dwight, Herbalife, and Bausch & Lomb provided commentary on challenges and what lies ahead. Highlights compiled by HBW Insight.



**Julie van Ongevalle**  
Executive VP, Consumer  
Healthcare at Sanofi

”

What we've seen in healthcare is that share of private labels have been relatively stable in the past two years. However, with increased inflation pressure and economic downturn, we are very conscious that consumers will have to make choices more than in the past.

But again, we've seen that in our area, consumers and patients make the least compromises. Again, health is definitely most important. And efficacy is a very strong loyalty driver, again, even more so in healthcare. And as a result, the quality and the value of our brands is what really makes a difference.

*28 July 2022*

Read more on [Sanofi's Q2 performance](#).



**Heiko S.**  
Consumer Health  
at B.